Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Investigating the Neuropsychological Effects of 5-HT2a Antagonism
NCT07022366Recruiting
- Sponsor
- University of Oxford
- Start
- Feb 2025
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial in major depressive disorder (MDD) comparing Pimavanserin with Placebo (2 arms). Primary endpoint: Sensitivity to loss and reward. Started Feb 2025; status: recruiting.
02
Drugs
pimavanserin
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT07022366.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07022366.